BioLife Solutions (BLFS) Q4 2024 earnings summary

Executive summary

• Achieved five consecutive quarters of cell processing revenue growth, surpassing raised full-year guidance and solidifying leadership in cell and gene therapy tools.

• 2024 marked a pivotal year with strategic portfolio reshaping, focusing on cell and gene therapy enablement and divesting non-core assets to streamline operations and improve financials.

• Divested non-core freezer and biostorage businesses, strengthening focus on high-growth, high-margin proprietary products and ending 2024 with over $100 million in cash.

• Biopreservation media embedded in 17 approved therapies, with 8 more approvals or expansions expected in the next 12 months.

Financial highlights

• 2024 total revenue was $82.3M, down from $143M in 2023 due to divestitures, but GAAP gross margin doubled from 31% to 62%, generating $51M in gross margin dollars versus $44M in 2023.

• Q4 2024 total revenue rose 31% year-over-year to $22.7M; cell processing revenue grew 37% to $20.3M.

• Adjusted EBITDA in 2024 was $16M (19% of revenue), up from negative $5M in 2023; Q4 adjusted EBITDA was $4M.

• Cash, cash equivalents, and marketable securities totaled $109.2M at year-end 2024, up from $45M in 2023.

• Q4 2024 GAAP net loss was $2M ($0.04/share), improved from $7.2M ($0.16/share) prior year.

Outlook and guidance

• 2025 revenue guidance: $95.5M–$99M, representing 16%–20% growth over 2024.

• Cell processing platform expected to contribute $86.5M–$89M (18%–21% growth); EVO and SAW platform expected at $9M–$10M (3%–15% growth).

• Adjusted gross margin for 2025 expected in the mid-60s, with further adjusted EBITDA margin expansion and reduced GAAP net loss.

• Mid-20s adjusted EBITDA margin expected for 2025, with potential to reach 30%+ by 2026 depending on media growth.